

## 7 LITERATURVERZEICHNIS

1. Agrawal, S., Kandimalla, E. R. (2004). Antisense and siRNA as agonists of Toll-like receptors. *Nat. Biotechnol.* **22**, 1533-1537.
2. Amarzguioui, M., Prydz, H., (2004). An algorithm for selection of functional siRNA sequences. *Biochem. Biophys. Res. Commun.* **316**, 1050-1058.
3. Amarzguioui, M., Holen, T., Babaie, E., Prydz, H. (2003). Tolerance for mutations and chemical modifications in RNAi. *Nucleic Acids Res.* **31**, 589-595.
4. Ambros, V. (2004). The functions of animal microRNAs. *Nature* **431**, 350-355.
5. Arias, C. F., Dector, M. A., Segovia, L., Lopez, T., Camacho, M., Isa, P., Espinosa, R., Lopez, S. (2004). RNA silencing of rotavirus gene expression. *Virus Res.* **102**, 43-51.
6. Bai, J., Banda, N., Lee, N. S., Rossi, J. J., Akkina, R. (2002). RNA-based anti-HIV gene therapeutic constructs in SCID-hu mouse model. *Mol. Ther.* **6**, 770-782.
7. Banerjea, A., Li, M.-J., Bauer, G., remling, L., Lee, N.-S., Rossi, J., Akkina, R. (2003). Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34<sup>+</sup> progenitor cell-derived macrophages. *Mol. Ther.* **8**, 62-71.
8. Barroso-delJesus, A., Puerta-Fernandez, E., Romero-Lopez, C., Berzal-Herranz, R. (2004). An experimental method for selecting effective target sites and designing hairpin ribozymes. *Methods Mol. Biol.* **252**, 313-325.
9. Baulcombe, D. (2004). RNA silencing in plants. *Nature* **431**, 356-363.
10. Beigelman, L., McSwiggen, J. A., Draper, K. G., Gonzalez, C., Jensen, K., Karpeisky, A. M., Modak, A. S., Matulic-Adamic, J., DiRenzo, A. B., Haeberli, P., Sweedler, D., Tracz, D., Grimm, S., Wincott, F. E., Thackaray, V. G., Usman, N. (1995). Chemical modification of hammerhead ribozymes. *J. Biol. Chem.* **270**, 25702-25708.
11. Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., Agami, R., Ge, W., Cavet, G., Linsley, P. S., Beijersbergen, R. L., Bernards, R. (2004). A large-scale RNAi screen in human cells identifies new components of the p53 pathway. *Nature* **428**, 431-437.
12. Bhuyan, P. K., Karikó, K., Capodici, J., Lubinski, J., Hook, L. M., Friedman, H. M., Weissman, D. (2004). Short interfering RNA-mediated inhibition of herpes simplex virus type 1 gene expression and function during infection of human keratinocytes. *J. Virol.* **78**, 10276-10281.

13. Bitko, V., Barik, S. (2001). Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. *BMC Microbiol.* **1**, 34.
14. Bitko, V., Musiyenko, A., Shulyayeva, O., Barik, S. (2005). Inhibition of respiratory viruses by nasally administered siRNA. *Nat. Med.* **11**, 50-55.
15. Boden, D., Pusch, O., Lee, F., Tucker, L., Ramratnam, B. (2003). Human immunodeficiency virus type 1 escapes from RNA interference. *J. Virol.* **77** 11531-11535.
16. Bohula, E. A., Salisbury, A. J., Sohail, M., Playford, M. P., Riedemann, J., Southern, E. M., Macaulay, V. M. (2003). The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGFR1 transcript. *J. Biol. Chem.* **278**, 15991-15997.
17. Bondensgaard, K., Petersen, M., Singh, S. K., Rajwanshi, V. K., Kumar, R., Wengel, J., Jacobsen, J. P. (2000). Structural studies of LNA:RNA duplexes by NMR: Conformations and implications for RNase H activity. *Chem. Eur. J.* **6**, 2687-2695.
18. Bowden, E. T., Riegel, A. T. (2004). Tetracycline-regulated expression of hammerhead ribozymes in vivo. *Methods Mol. Biol.* **252**, 179-194.
19. Braasch, D. A., Jensen, S., Liu, Y., Kaur, K., Arar, K., White, M. A., Corey, D. R. (2003). RNA interference in mammalian cells by chemically-modified RNA. *Biochemistry* **42**, 7967-7975.
20. Bramlage, B., Luzzi, E., Eckstein, F. (2000). HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture. *Nucleic Acids Res.* **28**, 4059-4067.
21. Breaker, R. R. (2000). Making catalytic DNAs. *Science* **290**, 2095-2096.
22. Bridge, A. J., Pebemard, S., Ducraux, A., Nicoulaz, L., Iggo, R. (2003). Induction of an interferon response by RNAi vectors in mammalian cells. *Nat. Genet.* **34**, 263-264.
23. Brummelkamp, T. R., Bernards, R., Agami, R. (2002a). A system for stable expression of short interfering RNAs in mammalian cells. *Science* **296**, 550-553.
24. Brummelkamp, T. R., Bernards, R., Agami, R. (2002b). Stable suppression of tumorigenicity by virus-mediated RNA interference. *Cancer Cell* **2**, 243-247.
25. Cairns, M. J., Hopkins, T. M., Witherington, C., Wang, L., Sun, L.-Q. (1999). Target site selection for an RNA-cleaving catalytic DNA. *Nat. Biotechnol.* **17**, 480-486.
26. Cairns, M. J., Hopkins, T. M., Witherington, C., Sun, L.-Q. (2000a). The influence of arm length asymmetry and base substitution on the activity of the 10-23 DNA enzyme. *Antisense Nucleic Acid Drug Dev.* **10**, 323-332.
27. Cairns, M. J., King, A., Sun, L.-Q. (2000b). Nucleic acid mutation analysis using catalytic DNA. *Nucleic Acids Res.* **28**, e9.
28. Carmell, M. A., Zhang, L., Conklin, D. S., Hannon, G. J., Rosenquist, T. A. (2003). Germline transmission of RNAi in mice. *Nat. Struct. Biol.* **10**, 91-92.

29. Caterina, M. J., Schumacher, M. A., Tominaga, T. A., Rosen, T. A., Levine, J. D., Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. *Nature* **389**, 816-824.
30. Check, E. (2005). Gene therapy put on hold as third child develops cancer. *Nature* **433**, 674.
31. Chen, W., Yan, W., Du, Q., Fei, L., Liu, M., Ni, Z., Sheng, Z., Zheng, Z. (2004). RNA interference targeting VP1 inhibits foot- and mouth disease virus replication in BHK-21 cells and suckling mice. *J. Virol.* **78**, 6900-6907.
32. Chen, Y., Du, D., Wu, J., Chan, C. P., Tan, Y., Kung, H. F., He, M. L. (2003). Inhibition of hepatitis B virus replication by stably expressed shRNA. *Biochem. Biophys. Res. Commun.* **311**, 398-404.
33. Chiu, Y. L., Rana, T. M. (2003). siRNA function in RNAi: a chemical modification analysis. *RNA* **9**, 1034-1048.
34. Cieslak, M., Niwiarowska, J., Nawrot, M., Koziolkiewicz, M., Stec, W. J., Cierniewski, C. S. (2002). DNazymes to  $\beta_1$  and  $\beta_3$  mRNA down-regulate expression of the targeted integrins and inhibit endothelial cell capillary tube formation in fibrin and matrigel. *J. Biol. Chem.* **277**, 6779-6787.
35. Cieslak, M., Szymanski, J., Adamiak, R. W., Cierniewski, C. S. (2003). Structural rearrangements of the 10-23 DNzyme to  $\beta_3$  integrin subunit mRNA induced by cations and their relations to the catalytic activity. *J. Biol. Chem.* **278**, 47987-47996.
36. Clayton, J. (2004). The silent treatment. *Nature* **431**, 599-609.
37. Couch, R. B. (1996). Rhinoviruses. In Fields, B. N., Knipe, D. M., Howley, P. M., Chanock, R. M., Monath, T. P., Melnick, J. L., Roizman, B., Straus, S. E. (eds.) *Field's Virology 3<sup>rd</sup> edition*. Lippincott-Raven Publishers, Philadelphia, 713-734.
38. Couzin, J. (2002). Breakthrough of the year. Small RNAs make big splash. *Science* **298**, 2296-2297.
39. Crooke, S. T. (2000). Progress in antisense technology: the end of the beginning. *Methods Enzymol.* **131**, 3-45.
40. Crooke, S. T. (2004). Progress in antisense technology. *Annu. Rev. Med.* **55**, 61-95.
41. Czauderna, F., Fechtner, M., Dames, S., Aygun, H., Klippel, A., Pronk, G. J., Giese, K., Kaufmann, J. (2003). Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. *Nucleic Acids Res.* **31**, 2705-2716.
42. Das, A.T., Brummelkamp, T. R., Westerhout, E. M., Vink, M., Madiredjo, M., Bernards, R., Berkhout, B. (2004). Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. *J. Virol.* **78**, 2601-2605.
43. Dass, C. R., Saravolac, E. G., Li, Y., Sun, L.-Q. (2002). Cellular uptake, distribution and stability of 10-23 Desoxyribozymes. *Antisense Nucleic Acid Drug Dev.* **12**, 289-299.
44. DeClercq, E. (2004). Antivirals and antiviral strategies. *Nat. Rev. Microbiol.* **2**, 704-720.

45. Dector, M. A., Romero, P., Lopez, S., Arias, C. F. (2002). Rotavirus gene silencing by small interfering RNAs. *EMBO Rep.* **3**, 1175-1180.
46. Ding, S.-W., Li, H., Lu, R., Li, F., Li, W.-X. (2004). RNA silencing: a conserved antiviral immunity of plants and animals. *Virus Res.* **102**, 109-115.
47. Doench, J. G., Sharp, P. A. (2004). Specificity of microRNA target selection in translational repression. *Genes Dev.* **18**, 504-511.
48. Dorsett, Y., Tuschl, T. (2004). siRNAs: applications in functional genomics and potential as therapeutics. *Nat. Rev. Drug Disc.* **3**, 318-329.
49. Doudna, J. A., Cech, T. R. (2002). The chemical repertoire of natural ribozymes. *Nature* **418**, 222-228.
50. Dove, A. (2002). Antisense and sensibility. *Nat. Biotechnol.* **20**, 121-124.
51. Earnshaw, D. J., Gait, M. J. (1998). Hairpin ribozyme cleavage catalysed by aminoglycoside antibiotics and the polyamine spermine in the absence of metal ions. *Nucleic Acids Res.* **26**, 5551-5561.
52. Eckstein, F. (2000). Phosphorothioate Oligodesoxynucleotides: what is their origin and what is unique about them? *Antisense Nucleic Acids Drug Dev.* **10**, 117-121.
53. Eddy, S. R. (2004). How do RNA folding algorithms work? *Nat. Biotechnol.* **22**, 1457-1458.
54. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**, 494-498.
55. Elbashir, S. M., Harborth, J., Weber, K., Tuschl, T. (2002). Analysis of gene function in somatic mammalian cells using small interfering RNAs. *Methods* **26**, 199-213.
56. Elmen, J., Thonberg, H., Ljungberg, K., Frieden, M., Westergaard, M., Xu, Y., Wahren, B., Liang, Z., Orum, H., Koch, T., Wahlestedt, C. (2005). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. *Nucleic Acids Res.* **33**, 439-447.
57. Fahmy, R. G., Khachigian, L. M. (2004). Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. *Nucleic Acids Res.* **32**, 2281-2285.
58. Feldman, A. R., Sen, D. (2001). A new and efficient DNA enzyme for the sequence-specific cleavage of RNA. *J. Mol. Biol.* **313**, 283-294.
59. Ferré-D'Amaré, A., Doudna, J. A. (1996). Use of cis- and trans-ribozymes to remove 5' and 3' heterogeneities from milligrams of in vitro transcribed RNA. *Nucleic Acids Res.* **24**, 977-978.
60. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806-811.
61. Galbraith, W. M., Hobson, W. C., Giclas, P. C., Schechter, P. J., Agrawal, S. (1994). Complement activation and hemodynamic changes following intravenous

- administration of phosphorothioate oligonucleotides in the monkey. *Antisense Res. Dev.* **4**, 201-206.
62. Gao, X., Wang, H., Sairenji, T. (2004). Inhibition of Epstein-Barr virus (EBV) reactivation by short interfering RNAs targeting p38 mitogen-activated protein kinase or c-myc in EBV-positive epithelial cells. *J. Virol.* **78**, 11798-11806.
63. Gautherot, I., Sodoyer, R. (2004). A multi-model approach to nucleic acid-based drug development. *Biodrugs* **18**, 37-50.
64. Ge, Q., McManus, M. T., Nguyen, T., Shen, C.-H., Sharp, P. A., Eisen, H. N., Chen, J. (2003). RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral transcription. *Proc. Natl. Acad. Sci. USA* **100**, 2718-2723.
65. Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H. N., Chen, J. (2004). Inhibition of influenza virus production in virus-infected mice by RNA interference. *Proc. Natl. Acad. Sci. USA* **101**, 8676-8681.
66. Giladi, H., Ketzinel-Gilad, M., Rivkin, L., Felig, Y., Nussbaum, O., Galun, E. (2003). Small interfering RNA inhibits hepatitis B virus replication in mice. *Mol. Therap.* **8**, 769-776.
67. Gitlin, L., Karelsky, S., Andino, R. (2002). Short interfering RNA confers intracellular antiviral immunity in human cells. *Nature* **418**, 430-434.
68. Gitlin, L., Stone, J. K., Andino, R. (2005). Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. *J. Virol.* **79**, 1027-1035.
69. Goila, R., Banerjee, A. C. (1998). Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammerhead ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme. *FEBS Lett.* **436**, 233-238.
70. Gray, D. M., Hung, S. W., Johnson, K. H. (1995). Absorption and circular dichroism spectroscopy of nucleic acid duplexes and triplexes. *Methods Enzymol.* **246**, 19-34.
71. Green, J., Casabonne, D., Newton, R. (2004). Coxsackie B virus serology and type I diabetes mellitus: a systematic review of published case-control studies. *Diabet. Med.* **21**, 507-514.
72. Grünweller, A., Wyszko, E., Bieber, B., Jahnel, R., Erdmann, V. A., Kurreck, J. (2003). Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. *Nucleic Acids Res.* **31**, 3185-3193.
73. Grünweller, A., Gillen, C., Erdmann, V. A., Kurreck, J. (2003). Cellular uptake and localization of a Cy3-labeled siRNA specific for the serine/threonine kinase Pim-1. *Oligonucleotides* **13**, 345-352.
74. Haasnoot, P. C. J., Cupac, D., Berkhout, B. (2003). Inhibition of virus replication by RNA interference. *J. Biomed. Sci.* **10**, 607-616.

75. Haley, B., Zamore, P. D. (2004). Kinetic analysis of the RNAi enzyme complex. *Nat. Struct. Mol. Biol.* **11**, 599-606.
76. Hamasaki, K., Nakao, K., Matsumoto, K., Ichikawa, T., Ishikawa, H., Eguchi, K. (2003). Short interfering RNA-directed inhibition of hepatitis B virus replication. *FEBS Lett.* **543**, 51-54.
77. Han, W., Wind-Rotolo, M., Kirkman, R. L., Morrow, C. D. (2004). Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. *Virology* **330**, 221-232.
78. Hannon, G. J., Rossi, J. J. (2004). Unlocking the potential of the human genome with RNA interference. *Nature* **431**, 371-377.
79. Hasuwa, H., Kaseda, K., Einarsdottir, T., Okabe, M. (2002). Small interfering RNA and gene silencing in transgenic mice and rats. *FEBS Lett.* **532**, 227-230.
80. Ho, S. P., Bao, Y., Leshner, T., Malhorta, R., Ma, L. Y., Fluharty, S. J., Sakai, R. R. (1998). Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. *Nat. Biotechnol.* **16**, 59-63.
81. Hogle, J. M. (2002). Poliovirus cell entry: common structural themes in viral cell entry pathways. *Annu. Rev. Microbiol.* **56**, 677-702.
82. Hogle, J. M., Chow, M., Filman, D. J. (1985). Three-dimensional structure of poliovirus at 2.9 Å resolution. *Science* **229**, 1358-1365.
83. Holen, T., Amarzguioui, M., Wiiger, M. T., Babaie, E., Prydz, H. (2002). Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. *Nucleic Acids Res.* **30**, 1757-1766.
84. Hu, W.-Y., Myers, C.-P., Kilzer, J. M., Pfaff, S. L., Bushman, F. D. (2002). Inhibition of retroviral pathogenesis by RNA interference. *Curr. Biol.* **12**, 1301-1311.
85. Hudson, A. J., Normand, N., Ackroyd, J., Akhtar, S. (1999). Cellular delivery of hammerhead ribozymes conjugated to a transferring receptor antibody. *Int. J. Pharm.* **182**, 49-58.
86. Hughes, M. D., Hussain, M., Nawaz, Q., Sayyed, P., Akhtar, S. (2001). The cellular delivery of antisense oligonucleotides and ribozymes. *Drug Discov. Today* **6**, 303-315.
87. Iversen, P. O., Nicolaysen, G., Sioud, M. (2001). DNA enzyme targeting TNF $\alpha$  mRNA improves hemodynamic performance in rats with postinfarction heart failure. *Am. J. Physiol. Heart Circ. Physiol.* **281**, H2211-2217.
88. Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi, S. V., Burchard, J., Mao, M., Li, B., Cavet, G., Linsey, P. S. (2003) Expression profiling reveals off-target gene regulation by RNAi. *Nat. Biotechnol.* **21**, 635-637.
89. Jepsen, J. S., Wengel, J. (2004). LNA-antisense rivals siRNA for gene silencing. *Curr. Opin. Drug Discov. Devel.* **7**, 188-194.
90. Ji, J., Wernli, M., Klimkait, T., Erb, P. (2003). Enhanced gene silencing by the application of multiple specific small interfering RNAs. *FEBS Lett.* **552**, 247-252.

91. Jiang, M., Milner, J. (2002). Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. *Oncogene* **21**, 6041-6048.
92. Joyce, G. F. (2001). RNA cleavage by the 10-23 DNA enzyme. *Methods Enzymol.* **341**, 503-517.
93. Kahana, R., Kuznetzova, L., Rogel, A., Shemesh, M., Hai, D., Yadin, H., Stram, Y. (2004). Inhibition of foot-and-mouth disease virus replication by small interfering RNA. *J. Gen. Virol.* **85**, 3213-3217.
94. Kanda, T., Kusov, Y., Yokosuka, O., Gauß-Muller, V. (2004). Interference of hepatitis A virus replication by small interfering RNAs. *Biochem. Biophys. Res. Commun.* **318**, 341-345.
95. Kapadia, S. B., Brideau-Andersen, A., Chisari, F. V. (2003). Interference of hepatitis C virus RNA replication by short interfering RNAs. *Proc. Natl. Acad. Sci. USA*, **100**, 2014-2018.
96. Karikó, K., Bhuyan, P., Capodici, J., Ni, H., Lubinski, J., Friedman, H., Weissman, D. (2004). Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. *Cells Tissues Organs* **177**, 132-138.
97. Kawasaki, H., Suyama, E., Iyo, M., Taira, K. (2003). siRNAs generated by recombinant human dicer induce specific and significant but target site-independent gene silencing in human cells. *Nucleic Acids Res.* **31**, 981-987.
98. Khachigian, L.M. (2002). DNazymes: cutting a path to a new class of therapeutics. *Curr. Opin. Mol. Ther.* **4**, 119-121.
99. Khvorova, A., Reynolds, A., Jayasena, S. D. (2003). Functional siRNAs and miRNAs exhibit strand bias. *Cell* **115**, 209-216.
100. Kim, K.-S., Hufnagel, G., Chapman, N. M., Tracy, S. (2001). The group B coxsackieviruses and myocarditis. *Rev. Med. Virol.* **11**, 355-368.
101. Klein, C., Bock, C. T., Wedemeyer, H., Wustefeld, T., Locarnini, S., Dienes, H. P., Kubicka, S., Manns, M. P., Trautwein, C. (2003). Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. *Gastroenterology* **125**, 9-18.
102. Konishi, M., Wu, C. H., Wu, G. Y. (2003). Inhibition of HBV replication by siRNA in a stable HBV-producing cell line. *Hepatology* **38**, 842-850.
103. Kretschmer-Kazemi Far, R., Sczakiel, G. (2003). The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. *Nucleic Acids Res.* **31**, 4417-4424.
104. Kronke, J., Kittler, R., Buchholz, F., Windisch, M. P., Pietschmann, T., Bartenschlager, R., Frese, M. (2004). Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. *J. Virol.* **78**, 3436-3446.
105. Kruger, K., Grabowski, P. J., Zaug, A. J., Sands, J., Gottschling, D. E., Cech, T. R. (1982). Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of *Tetrahymena*. *Cell*, **31**, 147-157.

106. Kühl, U., Pauschinger, M., Schwimmbeck, P. L., Seeberg, B., Lober, C., Noutsias, M., Poller, W., Schultheiß, H. P. (2003). Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. *Circulation* **107**, 2793-2798.
107. Kurreck, J. (2003). Antisense technologies: Improvement through novel chemical modifications. *Eur. J. Biochem.* **270**, 1628-1644.
108. Kurreck, J., Bieber, B., Jahnel, R., Erdmann, V. A. (2002a). Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. *J. Biol. Chem.* **277**, 7099-7107.
109. Kurreck, J., Wysko, E., Gillen, C., Erdmann, V. A. (2002b). Design of antisense oligonucleotides stabilized by locked nucleic acids. *Nucleic Acids Res.* **30**, 1911-1918.
110. Lan, N., Howrey, N. P., Lee, S.-W., Smith, C. A., Sullenger, B. A. (1998). Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. *Science* **280**, 1593-1596.
111. Le, S. Y., Zuker, M. (1990). common structures of the 5'non-coding RNA in enteroviruses and rhinoviruses. Thermodynamical stability and statistical significance. *J. Mol. Biol.* **216**, 729-741.
112. Le, S. Y., Maizel, J. V. Jr. (1998). Evolution of a common structural core in the internal ribosome entry sites of picornavirus. *Virus Genes* **16**, 25-38.
113. Lee, N. S., Bertrand, E., Rossi, J. J. (1999). mRNA localization signals can enhance the intracellular effectiveness of hammerhead ribozymes. *RNA* **5**, 1200-1209.
114. Lee, N. S., Rossi, J. J. (2004). Control of HIV-1 replication by RNA interference. *Virus Res.* **102**, 53-58.
115. Levin, A. A. (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. *Biochim. Biophys. Acta* **1489**, 69-84.
116. Li, Y., Wasser, S., Lim, S. G., Tan, T. M. (2004). Genome-wide expression profiling of RNA interference of hepatitis B virus gene expression and replication. *Cell Mol. Life Sci.* **61**, 2113-2124.
117. Lieber, A., Strauss, M. (1995). Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. *Mol. Cell Biol.* **15**, 540-551.
118. Lippmann, Z., Martienssen, R. (2004). The role of RNA interference in heterochromatic silencing. *Nature* **431**, 364-370.
119. Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J. J., Hammond, S. M., Joshua-Tor, L., Hannon, G. J. (2004). Argonaute 2 is the catalytic engine of mammalian RNAi. *Science* **305**, 1437-1441.
120. Lu, A., Zhang, H., Zhang, X., Wang, H., Hu, Q., Shen, L., Schaffhausen, B. S., Hou, W., Li, L. (2004). Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase. *Virology* **324**, 84-89.



121. Lu, W. W., Hsu, Y. Y., Yang, J. Y., Kung, S. H. (2004). Selective inhibition of enterovirus 71 replication by short hairpin RNAs. *Biochem. Biophys. Res. Commun.* **325**, 494-499.
122. McCaffrey, A. P., Meuse, L., Pham, T. T., Conklin, D. S., Hannon, G. J., Kay, M. A. (2002). RNA interference in adult mice. *Nature* **418**, 38-39.
123. McCaffrey, A. P., Nakai, H., Pandey, K., Huang, Z., Salazar, F. H., Xu, H., Wieland, S. F., Marion, P. L., Kay, M. A. (2003). Inhibition of hepatitis B virus in mice by RNA interference. *Nat. Biotechnol.* **21**, 639-644.
124. McCown, M., Diamond, M. S., Pekosz, A. (2003). The utility of siRNA transcripts produced by RNA polymerase I in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. *Virology* **313**, 514-524.
125. Meister, G., Tuschl, T. (2004). Mechanism of gene silencing by double-stranded RNA. *Nature* **431**, 343-349.
126. Michienzi, A., Castanotto, D., Lee, N., Li, S., Zaia, J., Rossi, J. J. (2003). RNA-mediated inhibition of HIV in a gene-therapy setting. *Ann. N. Y. Acad. Sci.* **1002**, 63-71.
127. Mittal, V. (2004). Improving the efficiency of RNA interference in mammals. *Nature Rev. Gen.* **5**, 355-365.
128. Miyagishi, M., Hayashi, M., Taira, K. (2003). Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. *Antisense Nucleic Acid Drug Dev.* **13**, 1-7.
129. Modrow, S., Falke, D., Truyen, U. (2003). Picornaviren. In *Dieselben: Molekulare Virologie*. Spektrum Verlag Heidelberg/Berlin, 133-166.
130. Monia, B. P., Lesnik, E. A., Gonzales, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., Freier, S. M. (1993). Evaluation of 2'-modified oligonucleotides containing 2'-Desoxy gaps as antisense inhibitors of gene expression. *J. Biol. Chem.* **268**, 14514-14522.
131. Ni, Q., Chen, Z., Yao, H. P., Yang, Z. G., Liu, K. Z., Wu, L. L. (2004). Inhibition of human La protein by RNA interference downregulates hepatitis B virus mRNA in 2.2.15 cells. *World J. Gastroenterol.* **10**, 2050-2054.
132. Nissen, P., Hansen, J., Ban, N., Moore, P. B., Steitz, T. A. (2000). The structural basis of ribosome activity in peptide bond synthesis. *Science* **289**, 920-930.
133. Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., Riess, J., Lee, S.-K., Collman, R. G., Lieberman, J., Shankar, P., Sharp, P. A. (2002). siRNA-directed inhibition of HIV-1 infection. *Nat. Med.* **8**, 681-686.
134. Novina, C. D., Sharp, P. A. (2004). The RNAi revolution. *Nature* **430**, 161-164.
135. Orba, Y., Sawa, H., Iwata, H., Tanaka, S., Nagashima, K. (2004). Inhibition of virus production in JC virus-infected cells by postinfection RNA interference.

136. Ota, N., Warashina, M., Hirano, K., Hatanaka, K., Taira, K. (1998). Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity. *Nucleic Acids Res.* **26**, 3385-3391.
137. Paddison, P. J., Silva, J. M., Conklin, D. S., Schlabach, M., Li, M., Aruleba, S., Balijs, V., O'Shaughnessy, A., Gnoj, L., Scobie, K., Chang, K., Westbrook, T., Cleary, M., Sachidanandam, R., McCombie, W. R., Elledge, S. J., Hannon, G. J. (2004). A resource for large-scale RNA-interference-based screens in mammals. *Nature* **428**, 427-431.
138. Peracchi, A. (2004). Prospects for antiviral ribozymes and Desoxyribozymes. *Rev. Med. Virol.* **14**, 47-64.
139. Phipps, K. M., Martinez, A., Lu, J., Heinz, B. A., Zhao, G. (2004). Small interfering RNA molecules as potential anti-human rhinovirus agents: in vitro potency, specificity and mechanism. *Antiviral Res.*, **61**, 49-55.
140. Plasterk, R. H. A. (2002). RNA silencing: the genome's immune system. *Science* **296**, 1263-1265.
141. Price, S. R., Ito, N., Oubridge, C., Avis, J. M., Nagai, K. (1995). Crystallization of RNA-protein complexes I. Methods for large-scale preparation of RNA suitable for crystallographic studies. *J. Mol. Biol.* **249**, 398-408.
142. Qin, X.-F., An, D. S., Chen, I. S. Y., Baltimore, D. (2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. *Proc. Natl. Acad. Sci. USA* **100**, 183-188.
143. Racaniello, V. R. (2001). Picornaviridae; the viruses and their replication. In: Knipe, D. M., Howley, P. M., Griffin, D. E., Lamb, R. A., Martin, M. A., Roizman, B., Straus, S. E. (eds.) *Field's Virology*, 4<sup>th</sup> edition. Lippincott Williams & Wilkins, Philadelphia, 685-722.
144. Radhakrishnan, S., Gordon, J., Del Valle, L., Cui, J., Khalili, K. (2004). Intracellular approach for blocking JC virus gene expression by using RNA interference during viral infection. *J. Virol.* **78**, 7264-7269.
145. Randall, G., Grakoui, A., Rice, C. M. (2003). Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. *Proc. Natl. Acad. Sci. USA* **100**, 235-240.
146. Rivera, V. M., Welsh, J. D., Maizel, J. V. (1988). Comparative sequence analysis of the 5'-non-coding region of the enteroviruses and rhinoviruses. *Virology* **165**, 42-50.
147. Romero, J. R. (2001). Pleconaril: a novel antipicornaviral drug. *Expert Opin. Investig. Drugs* **10**, 369-379.
148. Rossmann, M. G., Arnold, E., Erickson, J. W., Frankenberger, E. A., Griffith, J. P., Hecht, H. J., Johnson, J. E., Kramer, G., Luo, M., Moser, A. G., Rueckert, R. R., Sherry, B., Vriend, G. (1985). Structure of a human common cold virus and functional relationship to other picornaviruses. *Nature* **317**, 145-153.

149. Ryther, R. C. C., Flynt, A. S., Philips III, J. A., Patton, J. G. (2005). siRNA therapeutics: big potential from small RNAs. *Gene Ther.* **12**, 5-11.
150. Santiago, S. F., Lowe, H. C., Kavurma, M. M., Chesterman, C. N., Baker, A., Atkins, D. G., Khachigian, L. M. (1999). New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury. *Nat. Med.* **11**, 1264-1269.
151. Santoro, S. W., Joyce, G. F. (1997). A general purpose RNA-cleaving DNA enzyme. *Proc. Natl. Acad. Sci. USA*, **94**, 4262-4266.
152. Santoro, S. W., Joyce, G. F. (1998). Mechanism and utility of an RNA-cleaving DNA enzyme. *Biochemistry* **37**, 13330-13342.
153. Scherr, M., Reed, M., Huang, C. F., Riggs, A. D., Rossi, J. J. (2000). Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase. *Mol. Ther.* **2**, 26-38.
154. Schubert, S., Kurreck, J. (2004). Ribozyme- and Desoxyribozyme-strategies for medical applications. *Curr. Drug Tar.* **5**, 667-681.
155. Schubert, S., Kurreck, J. (2005). Oligonucleotide-based antiviral strategies. In: Erdmann, V. A., Brosius, J., Barciszewski, J. (eds.) RNA towards medicine. Springer-Verlag, Berlin / Heidelberg, Germany, *in press*.
156. Schubert, S., Gül, D. C., Grunert, H.-P., Zeichhardt, H., Erdmann, V. A., Kurreck, J. (2003). RNA cleaving „10-23“ DNazymes with enhanced stability and activity. *Nucleic Acids Res.* **31**, 5982-5992.
157. Schubert, S., Fürste, J. P., Werk, D., Grunert, H.-P., Zeichhardt, H., Erdmann, V. A., Kurreck, J. (2004). Gaining target access for deoxyribozymes. *J. Mol. Biol.* **339**, 355-363.
158. Schubert, S., Grunert, H.-P., Zeichhardt, H., Werk, D., Erdmann, V. A., Kurreck, J. (2005a). Maintaining inhibition: siRNA double expression vectors against coxsackieviral RNAs. *J. Mol. Biol.* **346**, 457-465.
159. Schubert, S., Grünweller, A., Erdmann, V. A., Kurreck, J. (2005b). Local RNA target structure influences siRNA efficacy: Systematic analysis of intentionally designed binding regions. *J. Mol. Biol.*, *in press*.
160. Schwarz, D. S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., Zamore, P. D. (2003). Asymmetry in the assembly of the RNAi enzyme complex. *Cell* **115**, 199-208.
161. Seksek O., Bolard J. (2004). Delivery agents for oligonucleotides. *Methods Mol. Biol.* **252**, 545-568.
162. Semizarov, D., Frost, L., Sarthy, A., Kroeger, P., Halbert, D. N., Fesik, S. W. (2003). Specificity of short interfering RNA determined through gene expression signatures. *Proc. Natl. Acad. Sci. USA* **100**, 6347-6352.
163. Sen, A., Steele, R., Ghosh, A. K., Basu, A., Ray, R., Ray, B. R. (2003). Inhibition of hepatitis C virus protein expression by RNA interference. *Virus Res.* **96**, 27-35.

164. Seo, M. Y., Abrignani, S., Houghton, M., Han, J. H. (2003). Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. *J. Virol.* **77**, 810-812.
165. Silva, J., Chang, K., Hannon, G. J., Rivas, F. V. (2004). RNA-interference based functional genomics in mammalian cells: reverse genetics coming of age. *Oncogene* **23**, 8401-8409.
166. Sioud, M. (2004). Therapeutic siRNAs. *Trends Pharmacol. Sci.* **25**, 22-28.
167. Sioud, M., Leirdal, M. (2000). Design of nuclease resistant protein kinase C $\alpha$  DNA enzymes with potential therapeutic application. *J. Mol. Biol.* **296**, 937-947.
168. Sledz, C. A., Holko, M., deVeer, M. J., Silverman, R. H., Williams, B. R. (2003). Activation of the interferon system by short-interfering RNAs. *Nat. Cell Biol.* **5**, 834-839.
169. Sohail, M., Southern, E. M. (2000). Selecting optimal antisense reagents. *Adv. Drug Deliv. Rev.* **44**, 23-34.
170. Song, E., Lee, S. K., Wang, J., Ince, N., Ouyang, N., Min, J., Chen, J., Shankar, P., Lieberman, J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitis. *Nat. Med.* **9**, 347-351.
171. Song, J. J., Smith, S. K., Hannon, G. J., Joshua-Tor, L. (2004). Crystal structure of argonaute and its implications for RISC slicer activity. *Science* **305**, 1434-1437.
172. Soutchek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Röhl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Kotliansky, V., Limmer, S., Manoharan, M., Vornlocher, H.-P. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* **432**, 173-178.
173. Stage-Zimmermann, T. K., Uhlenbeck, O. C. (1998). Hammerhead ribozyme kinetics. *RNA* **4**, 875-889.
174. Stein, C. A. (2001). The experimental use of oligonucleotides: a guide for the perplexed. *J. Clin. Invest.* **108**, 641-644.
175. Stewart, S. R., Semler, B. L. (1997). RNA determinants of picornavirus cap-independent translation initiation. *Semin. Virol.* **8**, 242-255.
176. Sullenger, B. A., Gilboa, E. (2002). Emerging clinical applications of RNA. *Nature* **418**, 252-258.
177. Sun, L.-Q., Cairns, M. J., Gerlach, W. J., Witherington, C., Wang, L., King, A. (1999). Suppression of smooth muscle cell proliferation by a c-myc RNA-cleaving Desoxyribozyme. *J. Biol. Chem.* **274**, 17236-17241.
178. Takahashi, H., Hamazaki, H., Habu, Y., Hayashi, M., Abe, T., Miyano-Kurosaki, N., Takaku, H. (2004). A new modified DNA enzyme that targets influenza virus A mRNA inhibits viral infection in cultured cells. *FEBS Lett.* **560**, 69-74.

179. Takigawa, Y., Nagano-Fujii, M., Deng, L., Hidajat, R., Tanaka, M., Mizuta, H., Hotta, H. (2004). Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome. *Microbiol Immunol.* **48**, 591-598.
180. Tang, G. (2005). siRNA and miRNA: an insight into RISCs. *Trends Biochem. Sci.* **30**, 106-114.
181. Tanner, N. K. (1999). Ribozymes: the characteristics and properties of catalytic RNAs. *FEMS Microbiol. Rev.* **23**, 257-275.
182. Thomas, C. E., Ehrhardt, A., Kay, M. A. (2003). Progress and problems with the use of viral vectors for gene therapy. *Nat. Rev. Genet.* **4**, 346-358.
183. Tomari, Y., Matranga, C., Haley, B., Martinez, N., Zamore, P. D. (2004). A protein sensor for siRNA asymmetry. *Science* **306**, 1377-1380.
184. Tompkins, S. M., Lo, C.-Y., Tumpey, T. M., Epstein, S. L. (2004). Protection against lethal influenza virus challenge by RNA interference in vivo. *Proc. Natl. Acad. Sci. USA* **101**, 773-778.
185. Uprichard, S. L., Boyd, B., Althage, A., Chisari, F. V. (2005). Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. *Proc. Natl. Acad. Sci. USA*, **102**, 773-778.
186. Usman, N., Blatt, L. M. (2000). Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. *J. Clin. Invest.* **106**, 1197-1202.
187. Vester, B., Lundberg, L. B., Sorensen, M. D., Babu, B. R., Douthwaite, S., Wengel, J. (2002). LNAzymes: incorporation of LNA-type monomers into DNAzymes markedly increases RNA cleavage. *J. Am. Chem. Soc.* **124**, 13682-13683.
188. Vester, B., Lundberg, L. B., Sorensen, M. D., Babu, B. R., Douthwaite, S., Wengel, J. (2004). Improved RNA cleavage by LNAzyme derivatives of DNAzymes. *Biochem. Soc. Trans.* **32**, 37-40.
189. Vickers, T. A., Wyatt, J. R., Freier, S. M. (2000). Effects of RNA secondary structure on cellular antisense activity. *Nucleic Acids Res.* **28**, 1340-1347
190. Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., Baker, B. F. (2003). Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. *J. Biol. Chem.* **278**, 7108-7118.
191. Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfeldt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., Ossipov, M., Koshkin, A., Jaobsen, N., Skouv, J., Orum, H., Jacobson, M. H., Wengel, J. (2000). Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. *Proc. Natl. Acad. Sci. USA* **97**, 5633-5638.
192. Wang, A., Cheung, P. K. M., Zhang, H., Carthy, C. M., Bohunek, L., Wilson, J. E., McManus, B. M., Yang, D. (2001). Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodesoxynucleotides. *Antimicrob. Agents Chemother.* **45**, 1043-1052.

193. Wang, L., Prakash, R. K., Stein, C. A., Koehn, R. K., Ruffner, D. E. (2003). Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo. *Antisense Nucleic Acids Drug Dev.* **13**, 169-189.
194. Wang, Q., Carmichael, G. G. (2004). Effects of length and location on the cellular response to double-stranded RNA. *Microbiol. Mol. Biol. Rev.* **68**, 432-452.
195. Wang, Z., Ren, L., Zhao, X., Hung, T., Meng, A., Wang, J., Chen, Y. G. (2004). Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. *J. Virol.* **78**, 7523-7527.
196. Warashina, M., Kuwabara, T., Nakamutsu, Y., Taira, K. (1999). Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome. *Chem. Biol.* **6**, 237-250.
197. Wells, V. R., Plotch, S. J., DeStefano, J. J. (2001). Determination of the mutation rate of poliovirus RNA-dependent RNA polymerase. *Virus Res.* **74**, 119-132.
198. Westerhout, E. M., Ooms, M., Vink, M., Das, A. T., Berkhout, B. (2005). HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. *Nucleic Acids Res.* **33**, 796-804.
199. Wiebusch, L., Truss, M., Hagemeyer, C. (2004). Inhibition of human cytomegalovirus replication by small interfering RNAs. *J. Gen. Virol.* **85**, 179-184.
200. Wilson, J. A., Jayasena, S., Khvorova, A., Sabatino, S., Rodrigue-Gervais, I. G., Arya, S., Sarangi, F., Harris-Brandts, M., Beaulieu, S., Richardson, C. D. (2003). RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. *Proc. Natl. Acad. Sci. USA* **100**, 2783-2788.
201. Xiang, W.-K., Paul, A. V., Wimmer, E. (1997). RNA signals in entero- and rhinovirus genome replication. *Semin. Virol.* **8**, 256-273.
202. Yokota, T., Sakamoto, N., Enomoto, N., Tanabe, Y., Miyagishi, M., Maekawa, S., Yi, L., Kurosaki, M., Taira, K., Watanabe, M., Mizusawa, H. (2003). Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. *EMBO Rep.* **4**, 602-608.
203. Yoon, J. S., Kim, S. H., Shin, M. C., Hong, S. K., Jung, Y. T., Khang, I. G., Shin, W. S., Kim, C. C., Paik, S. Y. (2004). Inhibition of herpesvirus-6B RNA replication by short interference RNAs. *J. Biochem. Mol. Biol.* **37**, 383-385.
204. Yoshinari, K., Miyagishi, M., Taira, K. (2004). Effects on RNAi of the tight structure, sequence and position of the targeted region. *Nucleic Acids Res.* **32**, 691-699.
205. Yu, R. Z., Geary, R. S., Monteith, D. K., Matson, J., Truong, L., Fitchett, J., Levin, A. A. (2004). Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. *J. Pharm. Sci.* **93**, 48-59.
206. Yuan, J., Cheung, P. K. M., Zhang, H., Chau, D., Yanagawa, B., Cheung, C., Luo, H., Wang, Y., Suarez, A., McManus, B. M., Yang, D. (2004). A phosphorothioate antisense oligodesoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts. *Lab. Invest.* **84**, 703-714.

207. Yuan, J., Cheung, P. K. M., Zhang, H. M., Chau, D., Yang, D. (2005). Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. *J. Virol.* **79**, 2151-2159.
208. Zaborowska, Z., Fürste, J. P., Erdmann, V. A., Kurreck, J. (2002). Sequence requirements in the catalytic core of the „10-23“ DNA enzyme. *J. Biol. Chem.* **277**, 40617-40622.
209. Zaborowska, Z., Schubert, S., Kurreck, J., Erdmann, V. A. (2005). Deletion analysis in the catalytic region of the 10-23 DNA enzyme. *FEBS Lett.* **579**, 554-558.
210. Zamecnik, P. C., Stephenson, M. L. (1978). Inhibition of Rous Sarcoma virus replication and cell transformation by a specific oligodesoxynucleotide. *Proc. Natl. Acad. Sci. USA* **75**, 280-284.
211. Zeichhardt, H., Grunert, H.-P. (2003). Enteroviruses: polioviruses, coxsackieviruses, echoviruses and enteroviruses 68-71. In: Cohen, J., Powderly, W. G., Opal, S. M. (eds.) *Infectious diseases 2<sup>nd</sup> edition*. Elsevier Health Sciences, London, 1993-2006.
212. Zender, L., Hutker, S., Liedtke, C., Tillmann, H. L., Zender, S., Mundt, B., Waltemathe, M., Gössling, T., Flemming, P., Malek, N. P., Trautwein, C., Manns, M. P., Kuhnel, F., Kubicka, S. (2003). Caspase 8 small interfering RNA prevents acute liver failure in mice. *Proc. Natl. Acad. Sci. USA* **100**, 7797-7802.
213. Zhang, J., Yamada, O., Sakamoto, T., Yoshida, H., Iwai, T., Matsushita, Y., Shimamura, H., Araki, H., Shimotohno, K. (2004). Down-regulation of viral replication by adenoviral-mediated expression of siRNA against cellular cofactors for hepatitis C virus. *Virology* **320**, 135-143.
214. Zhang, W., Singam, R., Hellermann, G., Kong, X., Juan, H. S., Lockey, R. F., Wu, S. J., Porter, K., Mohapatra, S. S. (2004). Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. *Genet. Vaccines Ther.* **2**, 8.
215. Zhang, W., Yang, H., Kong, X., Mohapatra, S., San Juan-Vergara H., Hellermann, G., Behera, S., Singam, R., Lockey, R. F., Mohapatra, S. S. (2005). Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. *Nat. Med.* **11**, 56-62.
216. Zhang, X. N., Xiong, W., Wang, J. D., Hu, Y. W., Xiang, L., Yuan, Z. H. (2004). siRNA-mediated inhibition of HBV replication and expression. *World J. Gastroenterol.* **10**, 2967-2971.
217. Zhang, X., Xu, Y., Ling, H., Hattori, T. (1999). Inhibition of infection of incoming HIV-1 virus by RNA-cleaving DNA enzyme. *FEBS Lett.* **458**, 151-156.
218. Zhang, Y., Li, T., Fu, L., Yu, C., Li, Y., Xu, X., Wang, Y., Ning, H., Zhang, S., Chen, W., Babiuk, L. A., Chang, Z. (2004). Silencing SARS-CoV spike protein expression in cultured cells by RNA interference. *FEBS Lett.* **560**, 141-146.
219. Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* **31**, 3406-3415.

**ANHANG A:**  
**VERZEICHNIS DER ABKÜRZUNGEN**

AAV	Adeno-Assoziiertes Virus	LNA	<i>Locked Nucleic Acid</i>
AIDS	<i>Acquired Immunodeficiency Disease Syndrome</i>	miRNA	micro RNA
AS-ODN	Antisense-Oligodesoxynukleotid	MOI	<i>multiplicity of infection</i>
ATP	Adenosintriphosphat	nt	Nukleotid, Nukleotide
c.p.m.	counts per minute	NTR	Nicht-translatierte Region
CAV	Coxsackievirus Gruppe A	OD	optische Dichte
CBV	Coxsackievirus Gruppe B	p.f.u.	<i>plaque forming units</i>
CPE	Cytopathischer Effekt	PEI	Polyethylenimin
DMEM	<i>Dulbecco's Modified Eagle's Medium</i>	PVDF	Polyvinylidenfluorid
EDTA	Ethylendiamin-tetraessigsäure	rasiRNA	<i>repeat associated small interfering RNA</i>
GFP	Grün fluoreszierendes Protein	RdRP	RNA-abhängige RNA Polymerase
HBV	Hepatitis B-Virus	RISC	<i>RNA induced silencing complex</i>
HCV	Hepatitis C-Virus	RNAi	RNA-Interferenz
HIV	Humanes Immunodefizienz-Virus	RNase	Ribonuklease
h.p.i.	<i>hours post infection</i> , Stunden nach Infektion	RSV	Respiratorisches Syncytial Virus
HRV	Humanes Rhinovirus	SARS-Virus	<i>Severe acute respiratory syndrome</i> -auslösendes Virus
IC <sub>50</sub>	<i>Inhibitory concentration</i> : Dosis, bei der halbmaximale Inhibition erreicht wird.	SCID	<i>Severe Combined Immunodeficiency Disease</i>
ICAM	<i>Intracellular Adhesion Molecule</i>	SDS	Natriumdodecylsulfat
IRES	Interne Ribosomen Eintritts-Sequenz	shRNA	<i>short hairpin RNA</i>
k <sub>cat</sub>	Ratenkonstante der Katalyse	SiDEx	siRNA Doppel-Expressionsvektor
K <sub>M</sub>	Michaelis-Menten Konstante	siRNA	<i>small interfering RNA</i>
k <sub>obs</sub>	beobachtete Reaktionskonstante	TLR	<i>Toll-like</i> Rezeptor
		v <sub>init</sub>	initial velocity, Anfangsgeschwindigkeit
		VPg	Virus Protein, Genomassoziiert
		VR1	Vanilloid Rezeptor Typ 1(=TPRV 1)